{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:25:23Z","timestamp":1756571123261,"version":"3.40.5"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T00:00:00Z","timestamp":1555113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The question of which chemotherapy induction provides the best results for indolent lymphoma patients is yet unanswered. Different regimens have been compared, none of which has been shown to improve overall survival. The use of bendamustine is growing. A number of trials evaluated its efficacy for patients with indolent B\u2010cell lymphoid neoplasms, including chronic lymphocytic leukaemia (<jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>). To evaluate the efficacy of bendamustine in that population we performed a systematic review and meta\u2010analysis of 9 randomised controlled trials (2726 patients). Bendamustine was compared to fludarabine\u2010containing regimens, <jats:styled-content style=\"fixed-case\">CVP<\/jats:styled-content> (cyclophosphamide, vincristine, prednisolone), <jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">CVP<\/jats:styled-content>+ doxorubicin) and chlorambucil. Due to insufficient reported data, six of the nine trials were included in analysis of overall survival. Bendamustine was associated with a prolonged overall survival, (hazard ratio 0\u00b779, 95% confidence interval 0\u00b765\u20130\u00b795). Data regarding quality of life was reported for two trials, therefore too scarce to pool. The risk of neutropenia was reduced with bendamustine treatment compared to other chemotherapy. Bendamustine induction is an efficacious option for patients with indolent lymphoma, and <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>. Maintenance therapy was not evaluated after bendamustine induction, and potentially there is an interaction between the two. Chemotherapy\u2010free approach was shown to be efficacious for patients with <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>, while toxicity with that approach is not negligible.<\/jats:p>","DOI":"10.1111\/bjh.15901","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T08:20:10Z","timestamp":1555143610000},"page":"234-242","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia \u2013 an updated meta\u2010analysis"],"prefix":"10.1111","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4137-1153","authenticated-orcid":false,"given":"Liat","family":"Vidal","sequence":"first","affiliation":[{"name":"Syneos Health Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronit","family":"Gurion","sequence":"additional","affiliation":[{"name":"Institute of Haematology Davidoff Centre Beilinson Hospital Rabin Medical Centre Petah Tikva Israel"},{"name":"Tel Aviv University Tel Aviv"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liat","family":"Shargian","sequence":"additional","affiliation":[{"name":"Institute of Haematology Davidoff Centre Beilinson Hospital Rabin Medical Centre Petah Tikva Israel"},{"name":"Tel Aviv University Tel Aviv"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Medizinische Klinik III Klinikum der Universit\u00e4t M\u00fcnchen\u2010Gro\u00dfhadern M\u00fcnchen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Gafter\u2010Gvili","sequence":"additional","affiliation":[{"name":"Tel Aviv University Tel Aviv"},{"name":"Department of Medicine A Beilinson Hospital Rabin Medical Centre Petah Tikva Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,4,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02530.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14480"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.14"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.01.012"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200110000-00003"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0023-2"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8960"},{"key":"e_1_2_6_13_1","unstructured":"Higgins JPT&Green S(eds).Cochrane Handbook for Systematic Reviews of Interventions\u00a0Version 5.1.0[updated March 2011]. The Cochrane Collaboration 2011. Available at:http:\/\/handbook.cochrane.org."},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8389"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12000"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819042000223822"},{"key":"e_1_2_6_18_1","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel N.","year":"1959","journal-title":"Journal of the National Cancer Institute"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.170480"},{"key":"e_1_2_6_20_1","unstructured":"NE Live Team. (2017)Health\u2010related Quality of Life of Patients Treated with FCR vs. BR within the CLL10 Trial. Available at:http:\/\/newevidence.live\/health-related-quality-of-life-of-patients-treated-with-fcr-vs-br-within-the-cll10-trial\/(Accessed November 30 2018)."},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1660-6"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.34877"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00447-7"},{"key":"e_1_2_6_26_1","first-page":"CD003805","article-title":"Chemotherapy plus Rituximab versus chemotherapy alone for B\u2010cell non\u2010Hodgkin's lymphoma","volume":"4","author":"Schulz H.","year":"2007","journal-title":"Cochrane Database Systematic Review"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn478"},{"key":"e_1_2_6_29_1","first-page":"CD009045","article-title":"Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia","volume":"9","author":"Vidal L.","year":"2012","journal-title":"Cochrane Database Systematic Review"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.021"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15901","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T20:59:20Z","timestamp":1694379560000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,13]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1111\/bjh.15901"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15901","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2019,4,13]]},"assertion":[{"value":"2018-12-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}